Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enzalutamide + fulvestrant
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
A combination therapy consisting of enzalutamide, an androgen receptor (AR) antagonist, and fulvestrant, a selective estrogen receptor degrader (SERD). This combination targets both hormonal pathways that may contribute to breast cancer progression by blocking androgen receptor signaling and inhibiting estrogen receptor dimerization and translocation into the nucleus while promoting proteasomal degradation of estrogen receptors. It has been investigated primarily for hormone receptor-positive breast cancer and has shown potential in overcoming resistance mechanisms to single-agent therapies.
- Brand names
- Xtandi + Faslodex
- Other names
- Enzalutamide and FulvestrantEnzalutamide plus Fulvestrant
02
Targets
AR (Adrenergic receptors)ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on enzalutamide + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enzalutamide + fulvestrant.